Monday, 18 Mar 2019

You are here

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Investigators performed a retrospective cohort review of 77 sJIA patients enrolled from 15 Italian centers who were treated with either anakinra (ANA) and canakinumab (CAN). The mean age of these patients was 12.7 years and mean sJIA disease duration was 4 years.

The retention rate of these IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9%, 59.5%, 53.%5, and 53.5%, respectively.

While the differences were not statistically different between ANA and CAN, the cumulative survival (retention) trended in favor of CAN, without concomitant DMARD (p = 0.056) and with concomitant DMARD use (p = 0.058).  Survival was significantly better with first time use of an IL-1 inhibitor.

Adverse events were significantly more frequent in those previously treated with biologic drugs (p = 0.038) compared to biologic naive patients.

Those with a higher risk of IL-1 inhibitors withdrawal included patients previously treated with other biologics (HR = 3.357 [CI: 1.341-8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186-7.435], p = 0.020).

These data suggest an excellent overall for both ANA and CAN, especially when used first line to manage sJIA.

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.

Biologic High Out of Pocket Costs for Medicare Patients

Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern.